Article Text

Download PDFPDF

1827 An Experience of Usage of Acellular DTAP Vaccine in Children Over 4 Years Old
  1. A Gayvoronskaya,
  2. M Galitskaya,
  3. T Grechukha
  1. Scientific Centre of Children’s Health, Moscow, Russia


Actuality: Pertussis is a high contagious bacterial infection with an air-drop way of transmission, remains a serious problem as in Russia, as all over the world. The only reliable way of prevention is immunization. The booster dose against pertussis injects at the age of one and a half years by the integral cellular DTP vaccine. In connection with the decrease of intensiry of immunity in 4–6 years after it, especially among children of school age, teenagers and adults, pertussis grows in these age groups. It is necessary to apply less reaktogenny acellular DTaP vaccine.

Purpose To estimate the shipping of DTaP vaccine in children over 4 years old as healthy, as with different deviations in a state of health.

Materials and Methods 83 children were immunized at the age of 4–12 years old: 29 health children and 54 children with various chronic diseases. The shipping of immunization was analysed.

Results Side effects, which have developed in first 3 days after immunization, have been noted at 27.7% of children with allergic pathology. All of them were moderate degree of expressiveness (temperature not higher than 38.5 C, hyperemia no more than 4–5 sm). Noone strong reactions were fixed.

Conclusion DTaP vaccine showed well safety profile, side effects in children with allergic pathology were moderate, had a shirt-term. DTaP vaccine is recommended as a booster dose in children at the age of 6–7 years old for inclusion to the National Calendar of inoculation of Russia.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.